{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Researchers Find New Mechanism of Chemotherapy Resistance in TNBC

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Evaluate the relationship found between inosine monophosphate dehydrogenase 2 (IMPDH2) and triple-negative breast cancer (TNBC) prognosis and treatment resistance.
  2. Explain the potential implications of these findings for the treatment of TNBC.

Learning Outcomes

By the conclusion of this activity, a majority of the participants will demonstrate knowledge of a study that identified a key driver of chemotherapy-resistance in triple-negative breast cancer, paving the way for more effective treatment strategies, by achieving a passing score on the posttest.
Price: $12.95

Credits:

  • ANCC 1.0 CH
  • DC - BON 1.0 CH
  • FL - BON 1.0 CH
  • GA - BON 1.0 CH
  • NM - BON 1.0 CH
  • SC - BON 1.0 CH
  • WV - BOERN 1.0 CH

Lippincott Professional Development is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.













Test Code: OT0425
Published: April 2025
Expires: 6/4/2027
Sources: Oncology Times
Required Passing Score: 4/5 (80%)
Authors: Catlin Nalley
Specialties: Oncology, Women's Health